郑州激光手术治疗眼睛多少钱(郑州近视初期怎么调整) (今日更新中)

BEIJING, Jan. 26 (Xinhua) -- China's civil affairs ministers visited survivors of last year's 7.1-magnitude Yushu earthquake and Zhouqu mudslide prior to China's lunar new year.Dou Yupei, vice minister of Civil Affairs, led a team to Yushu in northwest China's Qinghai Province to visit quake survivors and local cadres beginning on Sunday.Dou told Xinhua that quake survivors in Yushu now had access to food, clothing, safe drinking water, shelters and medical services, and the reconstruction of quake-damaged houses was well underway.Further, the ministry has distributed 45,000 cotton-padded tents to Yushu to house survivors during the extremely cold winter on the Qinghai-Tibet plateau.So far, 160,000 tents have been set up to assure that all survivors have a roof overhead, according to the ministry's statement issued Wednesday.Yushu was jolted by a 7.1-magnitude earthquake on April 14, leaving 2,200 people dead and 220,000 local residents affected.Another vice minister, Sun Shaocheng, visited survivors from a massive mudslide that left 1,700 people dead or missing in Zhouqu, Gansu province.To provide warm shelters to survivors, the Zhouqu county government invested three million yuan (455,000 U.S. Dollars) in renovating vacant school buildings or installing facilities in newly-built apartments.All survivors who previously had taken shelter in make-shift tents were relocated to these buildings before Oct. 13, according to the ministry's statement.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

SAN FRANCISCO, March 20 (Xinhua) -- Boeing's 747-8 Intercontinental took to the sky for the first time on Sunday, a milestone for the U.S. aviation giant's latest and biggest passenger plane.Live webcast by Boeing showed that a 747-8 Intercontinental touched down at around 2:25 p.m. PST (2125 GMT) Sunday at the Boeing Field airport in Seattle in the U.S. states of Washington, after wrapping up the airplane's inaugural flight that lasted about four and half hours.During the test flight, the pilots did some system and function checks and everything went fine, according to the webcast.The new 747-8 Intercontinental can carry 467 passengers in a three-class configuration, said Boeing, which touted the new wide- body jet airliner as the only airplane in the 400-500 seat market.The Boeing 747-8 Intercontinental takes off on its maiden flight from Paine Field, in Everett, Washington, March 20, 2011. The 747-8 Intercontinental willseat 467 passengers, 51 more than the latest model of the classic 747, and burn less fuel while offering passengers more comfort, the U.S. planemaker says.Using 787-technology GEnx engines, the airplane will be quieter, produce lower emissions and achieve better fuel economy for airlines, Boeing said.The airplane also features a new wing design and an upgraded flight deck. Its interior incorporates features from the Boeing 787 Dreamliner including a new curved, upswept architecture that will give passengers a greater sense of space and comfort, while adding more room for personal belongings.Boeing has noted that compared with its predecessor, the 747- 400, the 747-8 Intercontinental provides 16 percent better fuel economy, 16 percent less carbon emissions per passenger and generates 30 percent smaller noise footprint, while carries 51 more passengers.Boeing in February said that Korean Air, VIP customers and launch customer Lufthansa have ordered a total of 33 747-8 passenger planes, with the first delivery scheduled for the fourth quarter of this year.It is reported that the 747-8 Intercontinental has a list price of about 317 million U.S. dollars.Earlier in March, Boeing announced that it has signed an agreement with Air China for the purchase of five 747-8 Intercontinental jetliners.

WASHINGTON, May 11 (Xinhua) -- Researchers at Brigham and Women 's Hospital (BWH), a teaching affiliate of Harvard Medical School, have identified a human lung stem cell that is self-renewing and capable of forming and integrating multiple biological structures of the lung. This research will be published Thursday in the New England Journal of Medicine."This research describes, for the first time, a true human lung stem cell. The discovery of this stem cell has the potential to offer those who suffer from chronic lung diseases a totally novel treatment option by regenerating or repairing damaged areas of the lung," said the study's corresponding author Piero Anversa, who is also director of the Center for Regenerative Medicine at the hospital.Using lung tissue from surgical samples, researchers identified and isolated the human lung stem cell and tested the functionality of the stem cell both in vitro and in vivo. Once the stem cell was isolated, researchers demonstrated in vitro that the cell was capable of dividing both into new stem cells and also into cells that would grow into various types of lung tissue. Next, researchers injected the stem cell into mice with damaged lungs. The injected stem cells differentiated into new bronchioles, alveoli and pulmonary vessel cells which not only formed new lung tissue, but also integrated structurally to the existing lung tissue in the mice.The researchers define this cell as truly "stem" because it fulfills the three categories necessary to fall under stem cell categorization: first, the cell renews itself; second, it forms into many different types of lung cells; and third, it is transmissible, meaning that after a mouse was injected with the stem cells and responded by generating new tissue, researchers were then able to isolate the stem cell in the treated mouse, and use that cell in a new mouse with the same results."These are the critical first steps in developing clinical treatments for those with lung disease for which no therapies exist. Further research is needed, but we are excited about the impact this discovery could have on our ability to regenerate or recreate new lung tissues to replace damaged areas of the lungs," said Joseph Loscalzo, chair of the Department of Medicine at BWH and co-author.

BEIJING, Feb. 24 (Xinhua) -- The Standing Committee of the National People's Congress (NPC) will vote on draft laws on vehicle and boat taxes at the end of its bimonthly sessions on Friday.The group is also expected to vote on protecting the nation's intangible cultural heritage and a draft amendment to the Criminal Law.The Chairperson's Council of the NPC Standing Committee adopted the decision at a Thursday meeting presided over by NPC Standing Committee Chairman Wu Bangguo.The three drafts will undergo further deliberation and revision based upon the opinion of the members of the NPC Standing Committee before the laws are put to a vote.Under the draft law on vehicle and vessel taxes, there will be a reduction in taxes for vehicles with engines smaller than 2.0 liters, which accounts for 87 percent of China's cars. Vehicle owners would also be required to submit tax certificates in order to qualify for a road-worthiness certificate.

来源：资阳报